Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders
Investigation Announcement: Ademi LLP is investigating Pulmatrix for potential breaches of fiduciary duty related to its merger with Cullgen, where Pulmatrix shareholders will hold only 3.6% of the new entity.
Concerns Over Transaction Terms: The merger agreement restricts competing offers for Pulmatrix and provides significant benefits to insiders, raising questions about the board's adherence to their fiduciary responsibilities.
Trade with 70% Backtested Accuracy
Analyst Views on PULM
About PULM
About the author
Pulmatrix and Cullgen Update on Merger Approval Process
- Merger Agreement Progress: Pulmatrix and Cullgen have mutually agreed to waive the 'No Solicitation' clause in their merger agreement, allowing both parties to explore alternative transactions while still seeking approval from the China Securities Regulatory Commission, which could open new strategic collaboration opportunities.
- Regulatory Approval Delay: Despite Pulmatrix's merger agreement receiving shareholder approval in June 2025, the lack of approval from the China Securities Regulatory Commission may impact the final completion timeline of the merger and the company's future funding operations.
- Cash Flow Status: As of September 30, 2025, Pulmatrix reported a cash and cash equivalents balance of $4.8 million, which is anticipated to be sufficient to fund operations into the fourth quarter of 2026 based on current operational efficiencies and spending priorities, providing a financial buffer during the merger process.
- Clinical Assets and Technology: Pulmatrix focuses on developing inhaled therapeutic products for migraine and respiratory diseases using its proprietary iSPERSE™ technology, which aims to optimize drug delivery and improve patient outcomes, showcasing the company's innovative potential in the biopharmaceutical sector.
Pulmatrix and Cullgen Update on Merger Approval Process
- Merger Agreement Progress: Pulmatrix and Cullgen have mutually agreed to waive the 'No Solicitation' clause in their merger agreement, allowing both parties to explore alternative transactions while still seeking approval from the CSRC, which may open new opportunities for both companies.
- Regulatory Approval Delay: Despite Pulmatrix's merger agreement receiving shareholder approval in June 2025, the lack of approval from the CSRC may affect the final completion timeline of the merger, increasing uncertainty for stakeholders.
- Financial Position: As of September 30, 2025, Pulmatrix reported cash and cash equivalents of $4.8 million, which is anticipated to fund operations into the fourth quarter of 2026, indicating prudent financial management amidst ongoing merger discussions.
- Clinical Asset Development: Pulmatrix's iSPERSE™ technology shows promise across multiple clinical assets, particularly with PUR3100 receiving FDA IND approval and PUR1800 demonstrating favorable results in a Phase 1b study for AECOPD, suggesting potential market opportunities ahead.
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
Proposed Merger with Cullgen: Pulmatrix is advancing a merger with Cullgen, a biopharmaceutical company focused on targeted protein degradation therapies, while planning to divest its proprietary iSPERSE™ technology and related clinical programs, including a Phase 2-ready migraine treatment.
Financial Performance: In Q3 2025, Pulmatrix reported a decrease in revenues and operating expenses, with total cash and cash equivalents at $4.8 million, which is expected to sustain operations into Q4 2026.
Pulmatrix (PULM) Q2 Revenue Falls 100%
Financial Performance: Pulmatrix reported zero revenue in Q2 2025, with a net loss per share of $(0.42), significantly reduced from $(1.59) in the same quarter last year, primarily due to drastic cuts in R&D spending as the company winds down its clinical operations.
Strategic Focus: The company is concentrating on completing its merger with Cullgen and divesting its iSPERSE™ intellectual property and clinical programs, while offering no financial guidance for future quarters amid ongoing operational downsizing.
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
Proposed Merger Details: Pulmatrix, Inc. is set to merge with Cullgen, a clinical-stage biopharmaceutical company, anticipated to close in 2025, pending regulatory approvals and other conditions. The merger aims to create a Nasdaq-listed entity focused on targeted protein degradation therapies.
Divestment of iSPERSE™ Technology: As part of the merger, Pulmatrix plans to divest its proprietary iSPERSE™ dry powder delivery technology and related clinical programs, which are designed for inhalation-based drug delivery to treat various diseases, including migraines and respiratory conditions.
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
Proposed Merger with Cullgen: Pulmatrix, Inc. announced that its merger with Cullgen is expected to close in June 2025, which will lead to the creation of a Nasdaq-listed company focused on targeted protein degradation technology for cancer and pain treatment.
Divestment of Clinical Assets: As part of the merger, Pulmatrix plans to divest its clinical assets, including its Phase 2-ready migraine candidate PUR3100 and other development candidates utilizing its iSPERSE™ technology.
Pulmatrix and Cullgen Update on Merger Approval Process
- Merger Agreement Progress: Pulmatrix and Cullgen have mutually agreed to waive the 'No Solicitation' clause in their merger agreement, allowing both parties to explore alternative transactions while still seeking approval from the China Securities Regulatory Commission, which could open new strategic collaboration opportunities.
- Regulatory Approval Delay: Despite Pulmatrix's merger agreement receiving shareholder approval in June 2025, the lack of approval from the China Securities Regulatory Commission may impact the final completion timeline of the merger and the company's future funding operations.
- Cash Flow Status: As of September 30, 2025, Pulmatrix reported a cash and cash equivalents balance of $4.8 million, which is anticipated to be sufficient to fund operations into the fourth quarter of 2026 based on current operational efficiencies and spending priorities, providing a financial buffer during the merger process.
- Clinical Assets and Technology: Pulmatrix focuses on developing inhaled therapeutic products for migraine and respiratory diseases using its proprietary iSPERSE™ technology, which aims to optimize drug delivery and improve patient outcomes, showcasing the company's innovative potential in the biopharmaceutical sector.
Pulmatrix and Cullgen Update on Merger Approval Process
- Merger Agreement Progress: Pulmatrix and Cullgen have mutually agreed to waive the 'No Solicitation' clause in their merger agreement, allowing both parties to explore alternative transactions while still seeking approval from the CSRC, which may open new opportunities for both companies.
- Regulatory Approval Delay: Despite Pulmatrix's merger agreement receiving shareholder approval in June 2025, the lack of approval from the CSRC may affect the final completion timeline of the merger, increasing uncertainty for stakeholders.
- Financial Position: As of September 30, 2025, Pulmatrix reported cash and cash equivalents of $4.8 million, which is anticipated to fund operations into the fourth quarter of 2026, indicating prudent financial management amidst ongoing merger discussions.
- Clinical Asset Development: Pulmatrix's iSPERSE™ technology shows promise across multiple clinical assets, particularly with PUR3100 receiving FDA IND approval and PUR1800 demonstrating favorable results in a Phase 1b study for AECOPD, suggesting potential market opportunities ahead.
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
Proposed Merger with Cullgen: Pulmatrix is advancing a merger with Cullgen, a biopharmaceutical company focused on targeted protein degradation therapies, while planning to divest its proprietary iSPERSE™ technology and related clinical programs, including a Phase 2-ready migraine treatment.
Financial Performance: In Q3 2025, Pulmatrix reported a decrease in revenues and operating expenses, with total cash and cash equivalents at $4.8 million, which is expected to sustain operations into Q4 2026.
Pulmatrix (PULM) Q2 Revenue Falls 100%
Financial Performance: Pulmatrix reported zero revenue in Q2 2025, with a net loss per share of $(0.42), significantly reduced from $(1.59) in the same quarter last year, primarily due to drastic cuts in R&D spending as the company winds down its clinical operations.
Strategic Focus: The company is concentrating on completing its merger with Cullgen and divesting its iSPERSE™ intellectual property and clinical programs, while offering no financial guidance for future quarters amid ongoing operational downsizing.
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
Proposed Merger Details: Pulmatrix, Inc. is set to merge with Cullgen, a clinical-stage biopharmaceutical company, anticipated to close in 2025, pending regulatory approvals and other conditions. The merger aims to create a Nasdaq-listed entity focused on targeted protein degradation therapies.
Divestment of iSPERSE™ Technology: As part of the merger, Pulmatrix plans to divest its proprietary iSPERSE™ dry powder delivery technology and related clinical programs, which are designed for inhalation-based drug delivery to treat various diseases, including migraines and respiratory conditions.
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
Proposed Merger with Cullgen: Pulmatrix, Inc. announced that its merger with Cullgen is expected to close in June 2025, which will lead to the creation of a Nasdaq-listed company focused on targeted protein degradation technology for cancer and pain treatment.
Divestment of Clinical Assets: As part of the merger, Pulmatrix plans to divest its clinical assets, including its Phase 2-ready migraine candidate PUR3100 and other development candidates utilizing its iSPERSE™ technology.
